| Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease C Ma, MD Sacco, B Hurst, JA Townsend, Y Hu, T Szeto, X Zhang, ... Cell research 30 (8), 678-692, 2020 | 834 | 2020 |
| Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers SD Cady, K Schmidt-Rohr, J Wang, CS Soto, WF DeGrado, M Hong Nature 463 (7281), 689-692, 2010 | 731 | 2010 |
| Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L MD Sacco, C Ma, P Lagarias, A Gao, JA Townsend, X Meng, P Dube, ... Science Advances 6 (50), eabe0751, 2020 | 380 | 2020 |
| Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus J Wang, Y Wu, C Ma, G Fiorin, J Wang, LH Pinto, RA Lamb, ML Klein, ... Proceedings of the National Academy of Sciences 110 (4), 1315-1320, 2013 | 267 | 2013 |
| Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors C Ma, Y Hu, JA Townsend, PI Lagarias, MT Marty, A Kolocouris, J Wang ACS pharmacology & translational science 3 (6), 1265-1277, 2020 | 249 | 2020 |
| Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 B Boras, RM Jones, BJ Anson, D Arenson, L Aschenbrenner, ... Nature communications 12 (1), 6055, 2021 | 248 | 2021 |
| Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir Y Hu, EM Lewandowski, H Tan, X Zhang, RT Morgan, X Zhang, ... ACS central science 9 (8), 1658-1669, 2023 | 228 | 2023 |
| The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor Y Hu, X Meng, F Zhang, Y Xiang, J Wang Emerging microbes & infections 10 (1), 317-330, 2021 | 183 | 2021 |
| Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2 J Wang, C Ma, G Fiorin, V Carnevale, T Wang, F Hu, RA Lamb, LH Pinto, ... Journal of the American Chemical Society 133 (32), 12834-12841, 2011 | 172 | 2011 |
| Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay C Ma, MD Sacco, Z Xia, G Lambrinidis, JA Townsend, Y Hu, X Meng, ... ACS central science 7 (7), 1245-1260, 2021 | 171 | 2021 |
| Influenza virus A M2 protein generates negative Gaussian membrane curvature necessary for budding and scission NW Schmidt, A Mishra, J Wang, WF DeGrado, GCL Wong Journal of the American Chemical Society 135 (37), 13710-13719, 2013 | 160 | 2013 |
| Protein and small molecule microarrays: powerful tools for high-throughput proteomics M Uttamchandani, J Wang, SQ Yao Molecular BioSystems 2 (1), 58-68, 2006 | 160 | 2006 |
| Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus J Wang, JX Qiu, C Soto, WF DeGrado Current opinion in structural biology 21 (1), 68-80, 2011 | 144 | 2011 |
| Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors N Kitamura, MD Sacco, C Ma, Y Hu, JA Townsend, X Meng, F Zhang, ... Journal of medicinal chemistry 65 (4), 2848-2865, 2021 | 142 | 2021 |
| Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine … SD Cady, J Wang, Y Wu, WF DeGrado, M Hong Journal of the American Chemical Society 133 (12), 4274-4284, 2011 | 130 | 2011 |
| Discovery of a novel inhibitor of coronavirus 3CL protease for the potential treatment of COVID-19 B Boras, RM Jones, BJ Anson, D Arenson, L Aschenbrenner, ... BioRxiv, 2020.09. 12.293498, 2020 | 129 | 2020 |
| Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus V Balannik, J Wang, Y Ohigashi, X Jing, E Magavern, RA Lamb, ... Biochemistry 48 (50), 11872-11882, 2009 | 127 | 2009 |
| Discovery of di-and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity C Ma, Z Xia, MD Sacco, Y Hu, JA Townsend, X Meng, J Choza, H Tan, ... Journal of the American Chemical Society 143 (49), 20697-20709, 2021 | 124 | 2021 |
| Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus J Wang, C Ma, J Wang, H Jo, B Canturk, G Fiorin, LH Pinto, RA Lamb, ... Journal of medicinal chemistry 56 (7), 2804-2812, 2013 | 121 | 2013 |
| Progress and challenges in targeting the SARS-CoV-2 papain-like protease H Tan, Y Hu, P Jadhav, B Tan, J Wang Journal of medicinal chemistry 65 (11), 7561-7580, 2022 | 120 | 2022 |
Chunlong MaResearch specialistpharmacy.arizona.edu의 이메일 확인됨
